Important Update on Listing Status and Strategic Direction
Important Update on Listing Status and Strategic Direction
Important Update on Listing Status and Strategic Direction
有關上市狀況和戰略方向的重要更新
Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) — Nemaura Medical Inc. ("Nemaura Medical" or the "Company"), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital Market and our broader strategic direction.
英國拉夫堡，2024年1月3日（GLOBE NEWSWIRE）——日用無創血糖傳感器和數字醫療項目的開發商Nemaura Medical Inc.（“Nemaura Medical” 或 “公司”）正在提供有關近期決策的重要更新，這些決定將影響Nemaura Medical在納斯達克資本市場的上市地位和我們更廣泛的戰略方向。
Background:
After thorough analysis, Nemaura Medical's Board of Directors and management team have made the strategic decision to accept Nasdaq's determination to delist Nemaura Medical and move to the OTC Markets. This decision arises from a careful consideration of several factors, including challenges outside of our control that have led to a significant attrition of the share price. In light of these circumstances, maintaining our Nasdaq listing would necessitate a substantial dilution of approximately 90%, a move we believe would not serve the best interests of our valued shareholders.
背景：
經過全面分析，Nemaura Medical的董事會和管理團隊做出了戰略決策，接受納斯達克將Nemaura Medical退市並進入場外交易市場的決定。這一決定源於對多個因素的仔細考慮，包括導致股價大幅流失的超出我們控制範圍的挑戰。鑑於這些情況，維持我們在納斯達克的上市將需要大幅稀釋約90％，我們認爲此舉不符合我們尊貴股東的最大利益。
Benefits of the OTC Markets:
The transition to the OTC Markets will provide operational flexibility, reduced compliance costs, and the ability to focus on long-term growth without the immediate pressures associated with maintaining a Nasdaq listing.
場外交易市場的好處：
向場外交易市場的過渡將提供運營靈活性，降低合規成本，並能夠專注於長期增長，而無需承受與維持納斯達克上市相關的直接壓力。
Strategic Partnerships:
Committed to creating shareholder value, we are actively pursuing strategic partnerships critical to driving Nemaura Medical's growth. We believe these partnerships will play a key role in securing the necessary funding to propel innovation, expand market presence, and enhance our overall competitiveness.
戰略伙伴關係：
我們致力於創造股東價值，正在積極尋求對推動Nemaura Medical增長至關重要的戰略合作伙伴關係。我們相信，這些夥伴關係將在確保必要的資金以推動創新、擴大市場佔有率和增強我們的整體競爭力方面發揮關鍵作用。
Shareholder Role in Our Future Success:
We understand that this decision may raise questions and concerns. We want to assure shareholders that we remain committed to open and transparent communication. We value shareholder trust and support and are dedicated to keeping shareholders informed throughout this transition.
股東在我們未來成功中的作用：
我們知道這一決定可能會引發問題和擔憂。我們希望向股東保證，我們將繼續致力於公開和透明的溝通。我們重視股東的信任和支持，並致力於在整個過渡期間隨時向股東通報情況。
As we navigate this new phase, regular updates on our progress, strategic partnerships, and any material developments impacting shareholders will be provided. Additionally, in the near-term, we will continue to file annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K with the SEC. Please feel free to reach out to our Investor Relations team via email (IR@nemauramedical.com) with any questions or if further clarification is needed.
在我們進入這一新階段的過程中，將定期提供有關我們的進展、戰略伙伴關係以及任何影響股東的重大進展的最新情況。此外，在短期內，我們將繼續向美國證券交易委員會提交10-K表的年度報告，10-Q表的季度報告以及8-K表的最新報告。請隨時通過電子郵件聯繫我們的投資者關係團隊 (IR@nemauramedical.com）如有任何疑問或需要進一步澄清。
Thank you for your continued trust and confidence in Nemaura Medical. Together, we look forward to shaping a successful future.
感謝您一直以來對Nemaura Medical的信任和信心。我們共同期待着塑造一個成功的未來。
About Nemaura Medical, Inc.
關於 Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical technology company developing and wearable diagnostic devices. The company is currently commercializing sugarBEAT and proBEAT. sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura Medical has submitted a proposal for a Modular PMA (Premarket Approval Application) application for sugarBEAT to the U.S. FDA, for its generation II, 24-hour sensor. proBEAT is a non-regulated version of sugarBEAT which combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service as a general wellness product as part of its BEATdiabetes program.
Nemaura Medical, Inc. 是一家開發可穿戴診斷設備的醫療技術公司。該公司目前正在將 SugarBeat 商業化 和 ProBeat. SugarBe是一款獲得 CE 標誌批准的 IiB 類醫療設備，是一種非侵入性、靈活的連續血糖監測儀 (CGM)，可提供從實時血糖測量值和每日血糖趨勢數據中得出的切實可行的見解，可以幫助糖尿病和糖尿病前期患者更好地管理、逆轉和預防糖尿病的發作。Nemaura Medical 已提交了 SugarBeat 模塊化 PMA（上市前批准申請）申請提案 向美國食品藥品管理局提交其第二代 24 小時傳感器。ProBeat 是 SugarBeat 的非監管版本，它結合了使用人工智能處理的非侵入性葡萄糖數據和數字醫療訂閱服務作爲普通健康產品作爲其 BEAT 的一部分糖尿病計劃。
Additionally, Nemaura Medical launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one's overall metabolic health and well-being. Nemaura Medical believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.
此外，Nemaura Medical還啓動了Miboko的測試版試驗，Miboko是一項新陳代謝健康和福祉計劃，使用非侵入性葡萄糖傳感器和人工智能移動應用程序，可幫助用戶了解某些食物和生活習慣如何影響一個人的整體代謝健康和福祉。Nemaura Medical認爲，多達一半的人口可以從監測新陳代謝健康和福祉的傳感器和程序中受益。
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.
該公司位於全球2型糖尿病市場（預計到2025年將達到近590億美元）、500多億美元的糖尿病前期市場和用於減肥和健康應用的可穿戴健康技術領域的交匯點，該行業預計到2023年將達到600億美元。
For more information, please visit www.NemauraMedical.com.
欲了解更多信息，請訪問 www.nemauramedical.com。
Cautionary Statement Regarding Forward-Looking Statements:
關於前瞻性陳述的警示聲明：
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT in the U.S., risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura Medical's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura Medical and its partners' ability to develop, market and sell proBEAT, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT digital health, and sugarBEAT. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The U.S. Food and Drug Administration (the "FDA") reserves the right to re-evaluate its decision that proBEAT qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura Medical's filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K, each as may be amended from time to time. Nemaura Medical undertakes no obligation to publicly update or revise any forward-looking statements.
本新聞稿中非歷史事實的陳述可能構成前瞻性陳述，這些陳述基於當前預期，存在風險和不確定性，可能導致未來的實際業績與此類陳述所表達或暗示的結果存在重大差異。這些風險和不確定性包括但不限於 ProBeat 的發佈 在美國，與監管狀況相關的風險以及未來開發和初步營銷工作的失敗、Nemaura Medical獲得更多商業合作安排的能力、與Nemaura Medical及其合作伙伴開發、營銷和銷售ProBeat的能力相關的風險和不確定性，是否有大量額外的股權或債務資本來支持其研究、開發和產品商業化活動，以及其研究、開發、監管批准、營銷和分銷計劃和戰略的成功，包括與兩個 ProBeat 相關的計劃和戰略 數字健康和 SugarBeat。無法保證該公司能夠憑藉其產品/服務進入CGM的部分或任何全球市場。美國食品藥品監督管理局（“FDA”）保留重新評估其決定 ProBeat 的權利 如果發現任何問題，例如設備引起的皮膚刺激或其他不良事件，以及任何影響患者安全的濫用行爲，以及美國食品和藥物管理局可能認爲合適的任何其他原因來確定該產品不符合一般健康產品的定義，則符合普通健康產品的資格。Nemaura Medical向美國證券交易委員會提交的文件中更詳細地確定並描述了這些風險和不確定性，包括但不限於其最近完成的財年的10-K表年度報告、10-Q表季度報告和8-K表最新報告，每份報告都可能不時修改。Nemaura Medical沒有義務公開更新或修改任何前瞻性陳述。
Investor Relations Contact:
投資者關係聯繫人：
譯文內容由第三人軟體翻譯。